Welcome to our dedicated page for Centessa Pharmaceuticals Plc news (Ticker: CNTA), a resource for investors and traders seeking the latest updates and insights on Centessa Pharmaceuticals Plc stock.
Centessa Pharmaceuticals Plc (Nasdaq: CNTA) is a clinical-stage biopharmaceutical company advancing novel therapies for sleep-wake disorders and immuno-oncology through its innovative asset-centric R&D model. This dedicated news hub provides investors and industry observers with essential updates on the company’s progress in developing transformational medicines.
Our curated collection of CNTA news offers timely access to official press releases, clinical trial milestones, and regulatory developments. Track updates on key programs including ORX750 for narcolepsy, LB101 immuno-oncology candidates, and strategic R&D decisions. The platform serves as a centralized resource for understanding Centessa’s scientific advancements and business trajectory.
Users will find verified information on trial results, partnership announcements, and technology innovations like the LockBody® platform. Content is organized to help stakeholders monitor progress across therapeutic areas while maintaining perspective on the company’s unique operational structure. All materials are sourced directly from company communications and reputable financial news outlets.
Bookmark this page for efficient tracking of CNTA’s evolving pipeline and corporate developments. Combine these updates with SEC filings and earnings materials for comprehensive analysis of Centessa’s position in the competitive biopharmaceutical landscape.
Schrödinger (Nasdaq:SDGR) and Centessa Pharmaceuticals (Nasdaq:CNTA) announced an exclusive collaboration to discover novel therapeutics targeting the orexin-2 receptor (OX2R), relevant for sleep disorders like narcolepsy. This partnership marks the first large-scale application of Schrödinger's computational platform in orexin agonist development, leveraging Orexia’s structural biology capabilities. Orexia will manage preclinical research and commercialization, while Schrödinger will receive upfront payments and potential royalties on global sales. The collaboration aims to explore orexin agonists for various disorders characterized by excessive daytime sleepiness.
Centessa Pharmaceuticals (Nasdaq: CNTA) has appointed David Grainger, PhD, as its new Chief Innovation Officer, enhancing its executive leadership team. Dr. Grainger, a key advisor since the company's formation, will oversee scientific and research activities, shaping the development of therapeutic candidates. His appointment aligns with Centessa's goals for clinical and pre-clinical milestones. Previously, Dr. Grainger co-founded 28 biotech companies and has extensive experience in drug development.
Centessa Pharmaceuticals has announced a $300 million financing agreement with Oberland Capital, significantly boosting its available capital to over $900 million. This funding will support the advancement of its clinical and pre-clinical programs and enable strategic business development. The financing structure includes interest-only senior secured notes for six years. The initial $75 million was funded on October 4, 2021, with further options for funding available. This strategic move comes after a positive Phase 2 trial readout and sets the stage for potential registrational studies.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced positive topline results from the Phase 2a trial of SerpinPC, a treatment for severe hemophilia A and B. The study showed an 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% for spontaneous joint bleeds in the highest dose tested. The drug was found to be well-tolerated, with minimal adverse events reported. The company plans to initiate a global registrational program and will host a conference call to discuss findings.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will participate in an analyst-led fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on September 14, 2021, at 5:00 p.m. ET. A live audio webcast will be available on the investor relations section of Centessa's website, with a replay accessible for 90 days post-event. Centessa focuses on bringing new medicines to patients through a specialized, asset-centric approach, targeting various therapeutic areas such as oncology and immunology.
Centessa Pharmaceuticals (NASDAQ: CNTA) successfully completed an initial public offering (IPO), raising gross proceeds of $379.5 million to support its clinical and preclinical programs. The leadership team has been strengthened with key appointments in various executive roles. Financial results for Q2 2021 show a cash position of $613.8 million, enabling operations through the end of 2023. R&D expenses rose to $18.1 million due to an expanded portfolio, while net loss increased to $41.5 million or $0.65 per share.
Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 5:30 p.m. ET. The company focuses on developing new medicines through an asset-centric model, emphasizing specialized teams for diverse therapeutic areas, including oncology, hematology, and immunology. Centessa owns ten asset-centric companies, ranging from discovery to late-stage development, allowing for strategic resource allocation and shared infrastructure.
Citi has been appointed by Centessa Pharmaceuticals to serve as the depositary bank for its American Depositary Receipt (ADR) program. Centessa's American Depositary Shares (ADSs) are listed on the Nasdaq under the symbol 'CNTA'. Dirk Jones from Citi expressed enthusiasm for supporting Centessa's ADR program and enhancing investor outreach through their global equity distribution network. Centessa aims to innovate the drug development process by applying an asset-centric R&D model across its ten subsidiaries, backed by centralized infrastructure.
Centessa Pharmaceuticals announced the full exercise of the underwriters' option to purchase an additional 2,475,000 American Depositary Shares (ADSs) at the IPO price of $20.00, raising total gross proceeds to $379.5 million. The IPO closing occurred on June 2, 2021, with the additional ADSs issued today. This offering reflects the firm's asset-centric model aimed at developing impactful medicines. Morgan Stanley, Goldman Sachs, Jefferies, and Evercore ISI managed the offering. A registration statement was declared effective by the SEC on May 27, 2021.
Centessa Pharmaceuticals announced the pricing of its initial public offering of 16,500,000 American Depositary Shares (ADSs) at $20.00 per ADS, totaling approximately $330 million in gross proceeds. The offering is expected to close on June 2, 2021, pending customary conditions, with shares trading on Nasdaq under the symbol "CNTA" starting May 28, 2021. The underwriters have a 30-day option to purchase an additional 2,475,000 ADSs. Morgan Stanley, Goldman Sachs, Jefferies, and Evercore ISI are managing the offering.
